GlaxoSmithKline (GSK) AI Stock Analysis

• Market Cap: £71.54B
• Dividend Yield: 3.35%
• Average Volume (3M): 8.54M
• Price to Earnings (P/E): 13.2
• Beta (1Y): 0.85
• Revenue Growth: 2.73%
• EPS Growth: 119.38%
• Country: UK
• Employees: 68,629
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.55
• Shares Outstanding: 4,060,827,400
• 10 Day Avg. Volume: 6,837,178
• 30 Day Avg. Volume: 8,542,213
• PEG Ratio: -0.44
• Price to Book (P/B): 4.02
• Price to Sales (P/S): 1.75
• P/FCF Ratio: 15.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £1,645.75
• Price Target Upside: -7.57% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 13

• Rating: 77 Outperform
• Price Target: 1,866.00p ▲(4.80% Upside)

GlaxoSmithKline's strong financial performance and positive earnings call sentiment are the most significant factors driving the stock score. The company's robust growth in specialty medicines and successful R&D efforts contribute positively. Technical analysis supports a bullish outlook, while valuation remains reasonable with an attractive dividend yield. Challenges in the U.S. vaccines market and clinical trial delays are noted but do not significantly detract from the overall positive outlook.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term financial health.

R&D and Pipeline Expansion

Successful R&D and pipeline expansion enhance GSK's competitive edge, ensuring a steady flow of innovative products to market.

Specialty Medicines Growth

Strong growth in specialty medicines underscores GSK's ability to capitalize on high-demand therapeutic areas, boosting long-term profitability.

Negative Factors

Challenges in U.S. Vaccines Market

Struggles in the U.S. vaccines market could hinder GSK's revenue growth and market share in a key segment.

Delay in Clinical Trials

Delays in clinical trials can postpone product launches, affecting GSK's ability to meet market demand and revenue targets.

Impact of Medicare Redesign

Medicare redesign impacts could reduce profitability in affected product areas, challenging GSK's financial performance.

GlaxoSmithKline Business Overview & Revenue Model

Company Description

GlaxoSmithKline (GSK) is a global healthcare company headquartered in Brentford, United Kingdom. It operates in three main sectors: Pharmaceuticals, Vaccines, and Consumer Healthcare. GSK develops and manufactures a wide range of products, including innovative medicines for respiratory, HIV, and oncology conditions, vaccines for diseases such as influenza and shingles, and consumer healthcare products like oral health, pain relief, and wellness solutions.

How the Company Makes Money

GSK generates revenue through multiple streams primarily from its Pharmaceuticals and Vaccines divisions. The company earns money by selling prescription medications and vaccines to healthcare providers, hospitals, and governments worldwide. Key revenue drivers include blockbuster drugs and vaccines that address significant health needs. Additionally, GSK has strategic partnerships and collaborations with other pharmaceutical companies and research institutions, enhancing its product pipeline and market reach. The Consumer Healthcare division also contributes to earnings by selling over-the-counter products directly to consumers through retail and online channels. GSK focuses on research and development to innovate and bring new products to market, which is crucial for sustaining its revenue streams in a competitive industry.

GlaxoSmithKline Financial Statement Overview

Summary

GlaxoSmithKline exhibits strong financial performance with significant revenue growth and healthy profit margins. The balance sheet shows improved leverage and solid returns on equity, though the reliance on debt remains notable. Cash flow generation is robust, with positive growth in free cash flow, although there is potential for better cash conversion.

Income Statement

GlaxoSmithKline demonstrates strong revenue growth with a 32.4% increase in TTM, alongside robust gross and net profit margins of 71.4% and 10.8%, respectively. The EBIT and EBITDA margins are healthy at 16.7% and 27.2%, indicating efficient operations. However, the net profit margin has slightly decreased compared to previous years, which could be a point of concern.

Balance Sheet

The company's debt-to-equity ratio of 1.17 shows a moderate level of leverage, which has improved from previous years, indicating better financial stability. The return on equity is strong at 24.2%, reflecting effective use of equity to generate profits. However, the equity ratio is relatively low, suggesting a higher reliance on debt financing.

Cash Flow

GlaxoSmithKline's free cash flow growth of 24.5% in TTM is a positive indicator of cash generation. The operating cash flow to net income ratio of 0.38 and free cash flow to net income ratio of 0.67 suggest good cash flow management. Despite this, the ratios indicate room for improvement in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	31.63B	31.38B	30.33B	29.32B	24.70B	34.10B
Gross Profit	22.68B	21.90B	21.25B	19.46B	16.34B	23.12B
EBITDA	9.08B	6.67B	9.14B	8.63B	6.45B	10.16B
Net Income	3.42B	2.58B	4.93B	14.96B	4.38B	5.75B
Balance Sheet
Total Assets	59.26B	59.46B	59.01B	60.15B	79.10B	80.43B
Cash, Cash Equivalents and Short-Term Investments	3.62B	3.89B	5.69B	7.88B	4.33B	6.37B
Total Debt	17.35B	16.99B	18.02B	20.99B	24.17B	27.15B
Total Liabilities	44.90B	46.38B	46.21B	50.05B	57.76B	59.62B
Stockholders Equity	14.79B	13.67B	13.35B	10.60B	15.05B	14.59B
Cash Flow
Free Cash Flow	5.20B	3.57B	4.42B	5.14B	5.02B	6.20B
Operating Cash Flow	7.72B	6.55B	6.77B	7.40B	7.95B	8.44B
Investing Cash Flow	-3.62B	-1.23B	-1.59B	-8.77B	-1.78B	2.16B
Financing Cash Flow	-3.60B	-4.73B	-5.64B	823.00M	-7.59B	-10.13B

GlaxoSmithKline Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1780.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GSK, the sentiment is Positive. The current price of 1780.5 is above the 20-day moving average (MA) of 1653.28, above the 50-day MA of 1560.83, and above the 200-day MA of 1442.19, indicating a bullish trend. The MACD of 50.10 indicates Negative momentum. The RSI at 77.37 is Negative, neither overbought nor oversold. The STOCH value of 95.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:GSK.

GlaxoSmithKline Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GSK	―	£71.54B	13.16	36.44%	3.35%	2.73%	119.38%
SN	―	£11.91B	32.35	9.30%	2.05%	2.51%	56.56%
AZN	―	£193.32B	30.11	20.09%	1.68%	11.89%	25.68%
HIK	―	£4.02B	13.71	15.66%	3.46%	3.73%	27.13%
CTEC	―	£4.84B	29.82	12.73%	2.06%	4.18%	37.65%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

GlaxoSmithKline Corporate Events

GSK Enhances Shareholder Value with Strategic Buyback

GSK plc has announced the repurchase of 180,000 ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. The shares, purchased at prices ranging from 1,669.50p to 1,761.00p, will be held in treasury, increasing the total to 254,413,344 treasury shares. This move is part of a broader strategy to manage capital and return value to shareholders, reflecting the company’s robust financial position and commitment to enhancing shareholder value.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £1345.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Program with Recent Purchase

GSK has announced the purchase of 320,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas SA, reflects GSK’s strategy to manage its capital structure and return value to shareholders. The shares will be held as treasury shares, and the company now holds 254,233,344 shares in treasury, with a total of 4,061,187,442 shares in issue. This buyback is part of a broader effort to enhance shareholder value and optimize the company’s financial flexibility.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Reports Strong Q3 2025 Performance and Upgrades Guidance

GSK has reported a strong performance for the third quarter of 2025, with sales reaching £8.5 billion, driven by significant growth in specialty medicines, vaccines, and general medicines. The company has upgraded its guidance for 2025, expecting turnover growth between 6% to 7%, core operating profit growth between 9% to 11%, and core EPS growth between 10% to 12%. This performance is attributed to robust sales in respiratory, oncology, and HIV segments, as well as strategic investments in R&D and pipeline advancements. GSK has also achieved four major new product approvals this year and is progressing with pivotal trials for future growth opportunities. The company remains committed to shareholder returns, declaring a dividend and continuing its share buyback program.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK’s GSK’227 Receives EU Orphan Drug Designation for Lung Cancer

GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK’227, has received Orphan Drug Designation from the European Medicines Agency for the treatment of pulmonary neuroendocrine carcinoma, including small-cell lung cancer. This designation highlights GSK’227’s potential to address significant unmet needs in this aggressive cancer type, which has limited treatment options and poor outcomes. The designation is based on promising early clinical data and supports GSK’s strategy to accelerate the development of antibody-drug conjugates across various solid tumors, reinforcing its position in the oncology market.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Program with Recent Purchase

GlaxoSmithKline (GSK) has announced the purchase of 166,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas SA, is part of a larger effort that has seen GSK acquire over 6.4 million shares since September 2025. The purchased shares will be held as treasury shares, and the company now holds a total of 253,913,344 shares in treasury, with a total of 4,061,507,442 shares in issue. This move is likely to impact the company’s share value and could influence shareholder decisions regarding their investments.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with Latest Purchase

GSK has announced the purchase of 555,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on October 24, 2025, is part of a broader strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, GSK holds 253,747,344 shares in treasury, with a total of 4,061,673,442 shares in issue, excluding treasury shares. The buyback program reflects GSK’s commitment to enhancing shareholder value and maintaining a robust financial position.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with Recent Purchase

GSK has announced the purchase of 366,000 of its own ordinary shares, as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on 23 October 2025, is part of a broader strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, GSK holds 253,192,344 shares in treasury, with a total of 4,062,224,575 shares in issue, impacting the voting rights and shareholding calculations for stakeholders.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK’s Blenrep Gains FDA Approval for Multiple Myeloma Treatment

GSK announced that the US FDA has approved Blenrep for treating relapsed or refractory multiple myeloma in adults who have undergone at least two prior therapies. This approval is based on the DREAMM-7 trial, which showed significant improvements in survival and progression-free survival. Blenrep is the only anti-BCMA treatment available in community settings, addressing a major patient need. GSK is advancing its clinical program to explore Blenrep’s potential in earlier treatment stages, with ongoing trials and future data submissions planned to further solidify its role in the multiple myeloma treatment landscape.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Program with Latest Purchase

GSK has announced the purchase of 248,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This move is part of a broader strategy initiated on September 30, 2025, which has seen the company repurchase over 5.3 million shares, aiming to enhance shareholder value and optimize capital structure. Following this transaction, GSK holds over 252 million shares in treasury, representing 6.22% of the company’s voting rights, a figure relevant for shareholder interest calculations under regulatory guidelines.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Unveils Low Carbon Ventolin Inhaler with Promising Phase III Results

GSK has announced positive results from its phase III clinical trials for a next-generation low carbon version of its Ventolin (salbutamol) metered dose inhaler (MDI). This new formulation, which uses an innovative low carbon propellant, shows therapeutic equivalence and safety comparable to the current version. If approved, it could reduce greenhouse gas emissions by 92% per inhaler, significantly impacting GSK’s carbon footprint and supporting global climate targets. The company plans to proceed with regulatory submissions, with a launch expected in 2026, offering a more sustainable option for patients with respiratory diseases.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK and Alector Discontinue Latozinemab Trials After Mixed Results

GSK and Alector announced the results of the INFRONT-3 clinical trial for latozinemab, a treatment for frontotemporal dementia due to a progranulin gene mutation. While the trial showed a significant effect on plasma progranulin concentrations, it did not demonstrate clinical benefits in slowing disease progression, leading to the discontinuation of further studies. Despite this setback, GSK remains committed to exploring the data for future research opportunities in neurodegeneration.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Share Buyback

GSK plc has announced the purchase of 250,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, part of a non-discretionary agreement, brings the total shares held in treasury to 252,578,344, representing 6.22% of the company’s voting rights. The buyback initiative is aimed at optimizing the capital structure and providing returns to shareholders, reflecting GSK’s strategic focus on enhancing shareholder value.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK’s Shingrix Prefilled Syringe Gains Positive CHMP Opinion

GSK announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion on the approval of Shingrix in a prefilled syringe format. This new presentation simplifies the administration process for healthcare professionals and is expected to receive marketing authorization in the EU by December 2025, potentially enhancing GSK’s market position in the shingles vaccine sector.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK’s Oral Antibiotic Shows Promise in Treating Complicated UTIs

GSK and Spero Therapeutics announced promising results from the phase III PIVOT-PO trial for tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs). The trial demonstrated that tebipenem HBr is non-inferior to intravenous imipenem-cilastatin, offering a potential new oral option that could reduce hospital stays for cUTI patients. This development is significant given the high healthcare costs and serious risks associated with cUTIs, often caused by multidrug-resistant pathogens. If approved, tebipenem HBr would be the first oral carbapenem antibiotic in the US, enhancing GSK’s anti-infectives portfolio and addressing antimicrobial resistance challenges.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with Recent Purchase

GSK has announced the purchase of 220,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas SA, reflects GSK’s strategy to manage its capital structure and potentially enhance shareholder value. The shares will be held as treasury shares, increasing the total to 252,328,344, while the total number of voting rights remains at 4,063,088,575. This move may influence shareholder calculations regarding their interests in the company.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Buyback

GSK has announced the purchase of 414,000 of its own ordinary shares as part of its ongoing buyback program, with shares being held as treasury stock. This transaction, executed through BNP Paribas SA, reflects GSK’s strategic financial management aimed at optimizing shareholder value. Following this purchase, GSK holds a total of 252,108,344 ordinary shares in treasury, with 4,063,308,575 shares remaining in issue, impacting the voting rights percentage and potentially influencing shareholder decisions.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with Recent Purchase

GSK plc has announced the purchase of 310,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas SA, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds 251,694,344 shares in treasury, with a total of 4,063,719,485 shares in issue, excluding treasury shares. The buyback program reflects GSK’s commitment to returning value to shareholders and optimizing its capital allocation.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Executives Acquire Shares Following Dividend Reinvestment

GSK announced the acquisition of American Depositary Shares (ADSs) by key company executives, including Dr. Hal Barron, James Ford, and Shobie Ramakrishnan, following the reinvestment of dividends paid to shareholders. These transactions, conducted on the New York Stock Exchange, reflect the company’s ongoing commitment to aligning executive interests with shareholder value, potentially enhancing stakeholder confidence in GSK’s market strategies.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Buyback

GSK has announced the purchase of 405,500 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, completed on October 15, 2025, reflects GSK’s strategic approach to managing its capital structure and enhancing shareholder value. Following this purchase, GSK holds 251,384,344 shares in treasury, with a total of 4,064,029,485 shares in issue, excluding treasury shares. The buyback program is significant for stakeholders as it indicates GSK’s confidence in its financial stability and commitment to returning value to shareholders.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Executives Increase Shareholdings Through Dividend Reinvestment

GSK plc announced an increase in notional interest in its ordinary shares for several key executives, including the CEO and CFO, following the reinvestment of dividends paid on October 9, 2025. This transaction, conducted on the London Stock Exchange, reflects the company’s ongoing commitment to aligning executive interests with shareholder value through its Deferred Annual Bonus Plan.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Continued Share Buyback

GSK has announced the purchase of 270,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, part of a larger initiative since September 2025, aims to enhance shareholder value by reducing the number of shares in circulation, thereby potentially increasing the value of remaining shares. The company now holds 250,978,844 shares in treasury, with a total of 4,064,434,985 shares in issue, impacting the voting rights and shareholding calculations for stakeholders.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Buyback

GSK plc announced the purchase of 340,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on October 13, 2025, reflects GSK’s strategy to manage its capital structure and enhance shareholder value, with the purchased shares being held as treasury shares. The buyback program is a significant move in maintaining the company’s market positioning and optimizing its financial operations.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK’s Shingrix Vaccine Gains Approval in China for Broader Use

GSK has announced that its Shingrix vaccine has been approved by the China National Medical Products Administration for use in adults aged 18 and over who are at increased risk of shingles due to immunodeficiency or immunosuppression. This approval marks Shingrix as the first and only vaccine available for this demographic in China, expanding its existing indication for adults aged 50 and over. The approval is significant given the high incidence of shingles in China, with approximately six million cases annually, and it underscores GSK’s commitment to protecting vulnerable populations and enhancing healthcare systems’ focus on disease prevention.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Executives Acquire Shares Through Dividend Reinvestment

GSK plc announced the acquisition of ordinary shares by several key executives, including the CEO and other senior leaders, through the reinvestment of dividends as part of the company’s Share Reward Plan. These transactions, conducted on the London Stock Exchange, reflect the company’s ongoing commitment to aligning the interests of its leadership with those of its shareholders, potentially impacting stakeholder confidence and market perception.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Program with Recent Purchase

GSK announced the purchase of 355,000 of its ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, conducted on October 10, 2025, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds a total of 250,368,844 shares in treasury, representing 6.16% of the voting rights, which may influence shareholder calculations under regulatory guidelines.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Executives Acquire Shares Under Reward Plan

GSK plc announced the acquisition of ordinary shares by several of its key executives under the company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involves notable figures such as CEO Emma Walmsley and CFO Julie Brown, among others, and reflects GSK’s commitment to aligning the interests of its leadership with those of its shareholders.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Continued Buyback Program

GSK has announced the purchase of 295,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, conducted through BNP Paribas SA, reflects the company’s strategy to manage its capital structure and enhance shareholder value, with the purchased shares held as treasury shares.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Program with Latest Purchase

GlaxoSmithKline (GSK) has announced the purchase of 308,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through BNP Paribas SA, will be held as treasury shares. This transaction is part of a broader strategy to manage the company’s capital structure and return value to shareholders, with GSK having purchased a total of 2,254,000 shares since the end of September 2025. The buyback is expected to impact the company’s voting rights structure, with 6.14% of voting rights now attributable to treasury shares.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Program with Recent Purchase

GlaxoSmithKline (GSK) has announced the purchase of 354,000 of its own ordinary shares as part of its ongoing buyback program. The shares, purchased at prices ranging from 1,597.50p to 1,611.50p, will be held as treasury shares. This move is part of a non-discretionary agreement with BNP Paribas SA, and since September 30, 2025, GSK has acquired a total of 1,946,000 shares. The company now holds 249,410,844 shares in treasury, with 4,065,997,695 shares in issue. This buyback strategy is likely aimed at optimizing capital structure and potentially enhancing shareholder value.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with Latest Purchase

GSK has announced the purchase of 340,000 of its own ordinary shares as part of its ongoing buyback program. This move, executed through BNP Paribas SA, reflects the company’s strategy to manage its capital structure and enhance shareholder value. The shares will be held as treasury shares, and this transaction increases the total number of shares held in treasury to 249,056,844, representing 6.12% of the company’s voting rights. This buyback is part of a broader initiative that has seen the company repurchase 1,592,000 shares since September 30, 2025, potentially impacting the company’s stock liquidity and market perception.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Share Buyback

GSK has announced the purchase of 350,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on October 3, 2025, is part of a broader strategy to optimize the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds a total of 248,716,844 shares in treasury, with the total number of voting rights in the company standing at 4,066,691,695. This move reflects GSK’s commitment to returning value to its shareholders and maintaining a strong market position.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Buyback

GSK plc announced the purchase of 335,000 of its own ordinary shares as part of its ongoing buyback program, with the shares held as treasury stock. This move is part of a non-discretionary agreement with BNP Paribas SA and reflects the company’s strategy to manage its capital structure, potentially enhancing shareholder value and market confidence.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Announces Total Voting Rights and Capital Update

GSK plc has announced its total voting rights and capital as of September 30, 2025. The company’s issued share capital consists of over 4.3 billion ordinary shares, with a total of approximately 4.07 billion voting rights available. This information is crucial for shareholders to determine their required notifications under the Financial Conduct Authority’s rules.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Buyback

GSK has announced the purchase of 305,000 ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, completed on September 30, 2025, reflects GSK’s strategic financial management to enhance shareholder value. The shares will be held as treasury shares, and following this purchase, GSK holds 247,769,844 shares in treasury, with a total of 4,067,637,496 shares in issue. This move is significant for stakeholders as it impacts the voting rights and share distribution, with treasury shares now accounting for 6.09% of the voting rights.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Initiates Third Tranche of £2 Billion Share Buyback Programme

GSK has announced the commencement of the third tranche of its £2 billion share buyback programme, which aims to return excess capital to shareholders and enhance earnings per share. This tranche, valued at up to £0.3 billion, will be executed through a non-discretionary agreement with BNP Paribas and is expected to be completed by December 2025, reflecting GSK’s strategic focus on optimizing shareholder value.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Appoints Luke Miels as CEO Designate

GSK has announced the appointment of Luke Miels as CEO Designate, who will take over full responsibilities as CEO from January 1, 2026. Miels, who has been with GSK since 2017 as Chief Commercial Officer, has played a key role in expanding the company’s specialty medicines portfolio. He will succeed Dame Emma Walmsley, who has significantly transformed GSK’s operations, including the creation of Haleon, a leader in consumer health. This leadership change marks a pivotal phase for GSK as it aims for long-term growth with sales expectations exceeding £40 billion by 2031.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Directors Acquire Shares, Signaling Confidence in Future

GSK plc announced the purchase of shares by several of its independent non-executive directors, including Wendy Becker, Elizabeth McKee Anderson, Charles Bancroft, Dr Hal Barron, Dr Anne Beal, Dr Hal Dietz, Dr Jeannie Lee, and Dr Vishal Sikka. These transactions, which took place on September 19, 2025, involved the acquisition of ordinary shares and American Depositary Shares (ADSs) on the London Stock Exchange and New York Stock Exchange, respectively. This move reflects the directors’ confidence in the company’s future prospects and may positively impact stakeholder perceptions.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Program with Latest Purchase

GSK has announced the purchase of 15,858 of its own ordinary shares as part of its ongoing buyback program, conducted through Merrill Lynch International. This transaction, which is part of a non-discretionary agreement made in June 2025, aims to manage the company’s capital structure and potentially enhance shareholder value. Following this purchase, GSK holds 247,464,844 shares in treasury, with a total of 4,067,938,124 shares in issue, excluding treasury shares. The move reflects GSK’s strategic financial management and impacts its voting rights, which now stand at 6.08% for treasury shares.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Latest Share Buyback

GSK has announced the repurchase of 209,886 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on September 17, 2025, is part of a larger strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, GSK holds 247,448,986 shares in treasury, with a total of 4,067,953,982 shares in issue. The buyback is expected to enhance shareholder value and reflects the company’s confidence in its financial health and future prospects.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Buyback

GlaxoSmithKline (GSK) has announced the repurchase of 210,377 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, reflects GSK’s strategic efforts to manage its capital structure and enhance shareholder value. The shares will be held as treasury shares, and the company now holds a total of 247,239,100 ordinary shares in treasury. The buyback is part of a non-discretionary agreement and contributes to the company’s financial strategy, potentially impacting shareholder voting rights and market perceptions.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK to Invest $30 Billion in U.S. R&D and Manufacturing

GSK has announced a significant investment of $30 billion in the United States over the next five years, aimed at enhancing research and development and supply chain infrastructure. This includes a $1.2 billion investment in advanced manufacturing facilities and digital technologies, which will create hundreds of skilled jobs and strengthen the company’s presence in the U.S. life sciences sector. The initiative highlights GSK’s commitment to innovation and its strategic focus on respiratory and cancer medicines, further solidifying its leadership in the biopharma industry.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Program with Latest Purchase

GSK has announced the purchase of 253,331 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, part of a non-discretionary agreement initiated in June 2025, brings the total number of shares held in treasury to 247,028,723, representing 6.07% of the company’s voting rights. The buyback strategy is aimed at optimizing the capital structure and returning value to shareholders, potentially impacting the company’s stock market performance and investor relations.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Continues Share Buyback Program with Latest Purchase

GSK has announced the purchase of 203,447 of its own ordinary shares as part of an ongoing buyback program, with the shares to be held in treasury. This transaction, executed through Merrill Lynch International, reflects GSK’s strategy to manage its capital structure and return value to shareholders. Following this purchase, GSK holds 246,775,392 shares in treasury, representing 6.07% of the voting rights, which may impact shareholder calculations under regulatory guidelines.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Program with Recent Purchase

GSK has announced the purchase of 205,355 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction is part of a non-discretionary agreement initiated in June 2025, and the shares will be held as treasury shares. The buyback program reflects GSK’s strategy to manage its capital structure and enhance shareholder value, with the company now holding 246,571,945 shares in treasury. The total number of voting rights in the company remains at 4,068,829,782.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with Recent Purchase

GSK announced the purchase of 205,355 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, conducted on the London Stock Exchange, is part of a non-discretionary agreement established in June 2025, and it contributes to the company’s strategy to manage its capital structure effectively, impacting the voting rights and shareholding structure.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Continued Share Buyback

GSK announced the repurchase of 213,147 of its ordinary shares as part of its ongoing buyback program, executed through its broker Merrill Lynch International. This transaction is part of a larger strategy initiated in June 2025, which has seen the company repurchase over 28 million shares. The shares will be held as treasury shares, affecting the company’s voting rights and share capital structure. This move is likely to impact shareholder value and market perception positively, as buybacks often signal confidence in the company’s financial health.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Executives Acquire Shares Under Reward Plan

GSK plc announced the acquisition of ordinary shares by several key executives under the company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of shares by the CEO, CFO, and other senior executives, reflecting their commitment to the company’s growth and aligning their interests with shareholders.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Continued Share Buyback

GSK has announced the purchase of 207,767 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which forms part of a non-discretionary agreement, increases the company’s treasury shares to 246,153,443, representing 6.05% of the voting rights. The buyback is part of GSK’s strategy to manage its capital structure and return value to shareholders.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with Recent Purchase

GSK has announced the purchase of 219,116 of its own ordinary shares as part of its ongoing buyback program. This transaction, conducted through Merrill Lynch International, is part of a non-discretionary agreement and contributes to the company’s efforts to manage its capital structure, potentially impacting shareholder value and market perception.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Treasury Holdings with Share Buyback

GlaxoSmithKline (GSK) has announced the repurchase of 219,116 of its ordinary shares as part of its ongoing buyback program. The shares were bought at a volume-weighted average price of 1,460.93 pence per share and will be held as treasury shares. This move is part of a non-discretionary agreement with Merrill Lynch International and reflects GSK’s strategy to manage its capital structure effectively. The repurchase increases the total number of shares held in treasury to 245,945,676, representing 6.04% of the company’s voting rights, which could impact shareholder calculations under the Financial Conduct Authority’s rules.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value Through Strategic Buyback

GSK has announced the repurchase of 276,710 ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This move is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this transaction, GSK now holds 245,726,560 shares in treasury, with a total of 4,069,675,167 shares in issue, affecting the voting rights and potentially impacting shareholder decisions.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Program with Recent Purchase

GSK has announced the purchase of 284,800 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which is part of a non-discretionary agreement, increases the company’s treasury shares to 245,449,850, with a total of 4,069,946,246 shares in issue. The buyback is a strategic move to manage the company’s capital structure and potentially enhance shareholder value by reducing the number of shares available in the market.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £1434.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Awards Shares to SVP Under 2025 Plan

GSK plc announced a transaction involving the award of ordinary shares to Victoria Whyte, the Senior Vice President and Company Secretary, under the company’s 2025 Share Value Plan. This transaction, which involved 10,050 shares at a price of £14.4250 each, reflects GSK’s ongoing commitment to aligning its leadership’s interests with shareholder value, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £1434.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Continues Share Buyback Program with Recent Purchase

GSK plc announced the repurchase of 232,912 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. The shares were acquired at prices ranging from 1,445.50p to 1,466.00p per share and will be held as treasury shares. This transaction is part of a larger strategy to manage the company’s capital structure and return value to shareholders, with GSK holding a total of 245,165,050 shares in treasury and 4,070,231,046 shares in issue.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Share Buyback

GSK plc has announced the purchase of 296,202 of its own ordinary shares as part of its ongoing buyback program. These shares, acquired through Merrill Lynch International, will be held as treasury shares, contributing to the company’s strategy to manage its capital structure and enhance shareholder value. Following this transaction, GSK holds 244,932,138 ordinary shares in treasury, representing 6.02% of the voting rights, while 4,070,463,958 shares remain in issue.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Treasury Holdings with Share Buyback

GlaxoSmithKline (GSK) has announced the purchase of 227,465 of its own ordinary shares as part of its ongoing buyback program. The shares, bought at prices ranging from 1,442.00p to 1,468.50p, will be held as treasury shares. This transaction, executed through Merrill Lynch International, increases GSK’s total treasury shares to 244,635,936, impacting the company’s voting rights and potentially influencing shareholder interests.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Announces Total Voting Rights and Capital Update

GSK plc has announced its total voting rights and capital as of August 31, 2025, which includes an issued share capital of over 4.3 billion shares, with a significant portion held in Treasury. The total number of voting rights stands at approximately 4.07 billion, a crucial figure for shareholders to determine their notification obligations under the Financial Conduct Authority’s rules.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with Recent Purchase

GSK announced the purchase of 252,588 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on August 29, 2025, is part of a larger effort to manage the company’s capital structure, with the purchased shares held as treasury shares. Following this purchase, GSK holds 244,408,471 shares in treasury, with a total of 4,070,987,625 shares in issue. The buyback program is a strategic move to enhance shareholder value and optimize the company’s financial position.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with New Purchase

GlaxoSmithKline (GSK) plc has announced the purchase of 252,588 of its own ordinary shares as part of its ongoing buyback program. The shares, purchased through Merrill Lynch International, will be held as treasury shares, contributing to a total of 244,408,471 shares in treasury and 4,070,987,625 shares in issue. This move is part of a non-discretionary agreement made earlier in the year and reflects GSK’s strategic financial management efforts.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Program with Latest Acquisition

GSK plc announced the purchase of 260,986 of its own ordinary shares as part of its ongoing buyback program. The shares were acquired through Merrill Lynch International and will be held as treasury shares. This transaction is part of a larger strategy initiated on June 4, 2025, which has seen the company purchase over 25 million shares. The buyback is intended to optimize the capital structure and enhance shareholder value, with the current treasury shares representing 5.99% of the company’s voting rights.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Share Buyback

GSK plc announced the purchase of 251,452 ordinary shares as part of its ongoing share buyback program, executed through Merrill Lynch International. The shares, bought at prices ranging from 1,460.00p to 1,487.50p, will be held as treasury shares, increasing GSK’s total treasury holdings to 243,658,730 shares. This move is part of a strategy to manage the company’s capital structure and return value to shareholders, reflecting GSK’s commitment to optimizing shareholder returns.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with Recent Repurchase

GSK has announced the repurchase of 243,639 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on August 22, 2025, is part of a broader strategy to manage the company’s capital structure and return value to shareholders, with the repurchased shares held in treasury. The buyback program reflects GSK’s commitment to enhancing shareholder value and optimizing its financial resources.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Continued Share Buyback

GSK has announced the repurchase of 238,918 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, part of a non-discretionary agreement, increases the total number of shares held in treasury to 243,163,639, representing 5.97% of the company’s voting rights. The buyback is part of GSK’s strategy to optimize its capital structure and enhance shareholder value.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Announces Transaction for Chief Digital Officer

GSK plc announced a transaction involving its Chief Digital and Technology Officer, Shobie Ramakrishnan, who will receive a cash payment following the vesting of an award under the GlaxoSmithKline Deferred Investment Award Programme. This transaction reflects the company’s ongoing commitment to rewarding its key personnel and may have implications for its financial management and stakeholder engagement.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Share Buyback

GSK plc announced the purchase of 214,694 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, is part of a non-discretionary agreement and aims to enhance shareholder value by holding these shares in treasury. The buyback program reflects GSK’s strategic focus on optimizing capital allocation and maintaining financial flexibility.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Share Buyback

GSK plc has announced the repurchase of 211,358 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. The shares, bought at prices ranging from 1,430.50p to 1,452.50p, will be held as treasury shares, contributing to a total of 242,710,027 shares in treasury. This move is part of a strategic effort to manage the company’s capital structure and enhance shareholder value, with the total number of voting rights in the company now standing at 4,072,681,707.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Executives Acquire ADSs Through Dividend Reinvestment

GSK plc has announced the acquisition of American Depositary Shares (ADSs) by two of its executives, Dr. Hal Barron and James Ford, through reinvestment of dividends in their respective savings plans. These transactions, conducted on the New York Stock Exchange, reflect the company’s ongoing commitment to aligning executive interests with shareholder value, potentially enhancing stakeholder confidence in GSK’s financial strategies.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Buyback

GSK announced the purchase of 221,293 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, conducted on the London Stock Exchange, reflects GSK’s strategic financial management and aims to optimize capital allocation, potentially enhancing shareholder value. Following this purchase, GSK holds 242,498,669 ordinary shares in treasury, with a total of 4,072,893,065 shares in issue, affecting the percentage of voting rights attributable to treasury shares.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Program with Latest Purchase

GSK has announced the purchase of 436,588 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which is part of a non-discretionary agreement, increases the total number of shares held in treasury to 242,277,376, representing 5.95% of the company’s voting rights. The buyback is intended to optimize the capital structure and return value to shareholders, reflecting GSK’s confidence in its financial health and future prospects.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK and iTeos Advance Immunotherapy Study for Lung Cancer

GlaxoSmithKline (GSK) and iTeos Therapeutics are conducting a Phase 2 study titled A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer. The study aims to evaluate the efficacy and safety of novel immunotherapy combinations compared to monotherapy in patients with high PD-L1 expression in advanced non-small cell lung cancer (NSCLC). This research is significant as it explores potential new treatments for a challenging cancer type.

GSK Advances Share Buyback Program with Latest Repurchase

GlaxoSmithKline (GSK) has announced the repurchase of 501,689 of its ordinary shares as part of its ongoing buyback program. The shares, purchased through Merrill Lynch International, will be held as treasury shares. This transaction is part of a non-discretionary agreement initiated on June 4, 2025, and contributes to the total of 23,706,405 shares repurchased since that date. The buyback program aims to manage the company’s capital structure effectively, impacting the total number of voting rights, which stands at 4,073,550,458.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Expands Share Buyback Programme with New Purchase

GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a larger effort that has seen the company buy back over 23 million shares since June 2025. The purchased shares will be held as treasury shares, and this move is expected to impact the company’s share capital structure by adjusting the number of voting rights, which now stands at 4,074,052,147.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with Recent Purchase

GSK has announced the purchase of 495,245 of its own ordinary shares as part of its ongoing buyback program, executed through its broker, Merrill Lynch International. This transaction, which took place on 12 August 2025, is part of a larger initiative that has seen the company repurchase over 22 million shares since June 2025. The shares will be held as treasury shares, impacting the company’s voting rights and share capital structure, with implications for shareholder interests and market positioning.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Executives Acquire Shares Under Reward Plan

GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of 18 ordinary shares at a price of £14.0845 per share by each executive. This move reflects the company’s commitment to aligning the interests of its leadership with those of its shareholders, potentially strengthening stakeholder confidence and reinforcing GSK’s market position.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Buyback

GSK plc has announced the purchase of 494,426 of its own ordinary shares as part of an ongoing buyback program, executed through Merrill Lynch International. This transaction is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value, with the purchased shares being held as treasury shares. The buyback program reflects GSK’s confidence in its financial health and its commitment to delivering value to its shareholders.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with Recent Share Acquisition

GSK has announced the purchase of 497,923 of its own ordinary shares as part of its ongoing share buyback program, executed through Merrill Lynch International. This transaction, which took place on August 8, 2025, reflects GSK’s strategic efforts to manage its capital structure and return value to shareholders. The shares were acquired at prices ranging from 1,389.50p to 1,405.50p and will be held as treasury shares, contributing to a total of 240,042,950 shares held in treasury. This move is part of a broader plan initiated on June 4, 2025, and highlights GSK’s commitment to enhancing shareholder value while maintaining a robust financial position.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK’s Gepotidacin Gains Priority Review for Gonorrhoea Treatment

GSK announced that the US FDA has accepted gepotidacin for priority review as an oral treatment for uncomplicated urogenital gonorrhoea, with a decision expected in December 2025. This new antibiotic option could replace current injectable treatments, addressing a significant public health need as gonorrhoea is a priority pathogen with rising resistance to existing therapies.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK and Ideaya’s Promising Study on Solid Tumors: A Potential Game-Changer?

GlaxoSmithKline (GSK) and Ideaya Biosciences are conducting a study titled A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER). The study aims to evaluate the safety, pharmacokinetics, and preliminary effectiveness of GSK4418959, alone or with a PD-1 inhibitor, in treating aggressive solid tumors with specific genetic traits.

GSK’s New Study on Multiple Myeloma Treatment: What Investors Need to Know

GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM). The study aims to evaluate whether the BRd combination can prolong progression-free survival and improve minimal residual disease negative status compared to the DRd regimen in patients with TI-NDMM.

GSK’s Promising Study on Belimumab for Lung Disease: What Investors Need to Know

GlaxoSmithKline (GSK) is currently conducting a Phase 2/3 clinical study titled ‘A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease.’ The primary goal is to assess the effectiveness and safety of belimumab, a biological treatment, in improving lung function and addressing other symptoms in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). This study is significant as it could offer a new therapeutic option for a condition with limited treatments.

GSK and iTeos Therapeutics’ Promising Phase 3 Lung Cancer Study: Market Implications

GlaxoSmithKline (GSK) and iTeos Therapeutics are conducting a Phase 3 clinical trial titled ‘GALAXIES Lung-301’ to assess the safety and efficacy of belrestotug combined with dostarlimab versus pembrolizumab with placebo in patients with high PD-L1 non-small-cell lung cancer (NSCLC). The study aims to determine if the new combination improves progression-free survival and overall survival compared to the current standard treatment.

GSK’s Phase 3 Study on Dostarlimab: A Potential Game-Changer in Colon Cancer Treatment?

GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled ‘A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer.’ The study aims to evaluate the efficacy of perioperative dostarlimab compared to the standard of care in patients with specific types of colon cancer, highlighting its potential significance in improving treatment outcomes.

GSK’s RSV Vaccine Study: A Potential Game-Changer for Older Adults

GlaxoSmithKline (GSK) is conducting a Phase 3 study in India to assess the immune response and safety of their RSVPreF3 OA investigational vaccine. The study targets older adults aged 60 and above, as well as adults aged 50-59 at increased risk of respiratory syncytial virus lower respiratory tract disease (RSV-LRTD). The goal is to evaluate the vaccine’s effectiveness in preventing RSV-LRTD in these populations.

GSK’s Phase 3 RSV Vaccine Study: Key Insights for Investors

GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Controlled, Partially Blind, Immuno-bridging Study to Evaluate Immunogenicity, Reactogenicity, Safety and the Occurrence of RSV Associated Respiratory Tract Illness After Administration of a Single Dose of GSK’s RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Older. The study aims to assess the immune response and safety of the RSVPreF3 OA vaccine in adults aged 60 and older, with a focus on comparing results between participants in China and those from other countries.

GSK’s RSV Vaccine Study: A Potential Game-Changer for Transplant Recipients

GlaxoSmithKline (GSK) has recently completed a Phase 2b clinical study titled ‘A Phase 2b, Randomized, Controlled, Open-label Study to Evaluate the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults (>=18 Years of Age) When Administered to Lung and Renal Transplant Recipients Comparing 1 Versus 2 Doses and Compared to Healthy Controls (>=50 Years of Age)’. The study aimed to assess the immune response and safety of the RSVPreF3 OA vaccine in immunocompromised adults who have received lung or kidney transplants, as well as in healthy adults aged 50 and above. This research is significant as it explores the potential of the vaccine to enhance immune response in vulnerable populations.

GSK Advances Share Buyback Program with Latest Purchase

GlaxoSmithKline (GSK) has announced the purchase of 502,466 of its own ordinary shares as part of its ongoing buyback program, executed through its corporate stockbroker Merrill Lynch International. This transaction is part of a non-discretionary agreement made on June 4, 2025, and contributes to the total of 21,410,644 shares purchased since that date. The purchased shares will be held as treasury shares, and this move is expected to impact the company’s share capital structure by maintaining a percentage of voting rights attributable to treasury shares at 5.88%.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Secures $370 Million Settlement in mRNA Patent Dispute

GSK has announced a settlement with CureVac and BioNTech regarding mRNA patent litigation, resulting in a $370 million upfront payment and a 1% royalty on future US sales of mRNA vaccines by Pfizer and BioNTech. This settlement, which will be recorded in GSK’s financial results, does not affect GSK’s ongoing patent enforcement against Pfizer and BioNTech in the US and Europe, and includes a tender agreement for GSK’s CureVac shares.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK’s New Study on GSK5764227: A Potential Game-Changer in Gastrointestinal Cancer Treatment

GlaxoSmithKline (GSK) is conducting a study titled ‘A Phase1b/2, Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors.’ The study aims to assess the safety and effectiveness of GSK5764227, a new biological treatment, in patients with advanced gastrointestinal cancers that cannot be surgically removed. This research is significant as it targets a patient group with limited treatment options.

GSK’s MenABCWY Vaccine Study: A Potential Game-Changer in Meningococcal Disease Prevention

GlaxoSmithKline (GSK) is conducting a Phase IIb clinical study titled A Phase IIb, Randomized, Observer-Blind Study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents. The study aims to evaluate the safety, tolerability, and immunogenicity of the MenABCWY vaccine, which targets five meningococcal serogroups to prevent invasive meningococcal disease (IMD) in adolescents.

GSK’s POPSTAR Study: A New Hope in Pediatric Cancer Treatment

GlaxoSmithKline (GSK) is conducting a clinical study titled ‘Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)’. The study aims to find the most tolerated dose of cobolimab and dostarlimab in children and young adults with advanced solid tumors, assess safety, manage side effects, and evaluate treatment effects.

GSK’s RSV Vaccine Study: Key Insights for Investors

GlaxoSmithKline (GSK) is currently conducting a Phase 3b clinical study titled An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study. The study aims to determine the optimal revaccination timing for the RSVPreF3 OA vaccine, assess long-term immune persistence and safety over five RSV seasons, and provide the vaccine to participants who previously received a placebo.

GSK’s New Clinical Study on Endometrial Cancer: What Investors Need to Know

GlaxoSmithKline (GSK) has announced a new clinical study titled A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Participants With dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer in China (China RUBY). The study aims to evaluate the effectiveness and safety of dostarlimab in combination with chemotherapy drugs carboplatin and paclitaxel in treating endometrial cancer (EC) among Chinese participants. This research is significant as it seeks to improve treatment outcomes for EC, focusing on drug behavior and immune response.

GSK Completes Promising Study on Gonorrhea Vaccine

GlaxoSmithKline (GSK) recently completed a Phase 1/2 clinical study titled ‘Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.’ The study aimed to evaluate the safety, efficacy, and immunogenicity of the NgG investigational vaccine compared to a placebo in healthy adults. This study is significant as it represents a first-in-human proof of concept for potentially preventing Neisseria gonorrhoeae infections.

GSK’s Promising Phase 2 Study on Myelofibrosis Treatment: A Potential Game-Changer

GlaxoSmithKline (GSK) is currently recruiting for a Phase 2 study titled ‘A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis.’ The study aims to assess the efficacy and safety of combining momelotinib and luspatercept in patients with transfusion-dependent myelofibrosis, a condition where patients require regular blood transfusions. This research is significant as it targets both JAK inhibitor-naïve and experienced patients, potentially offering a new treatment avenue.

GSK’s Phase 3 Malaria Study: A Potential Game-Changer for Tafenoquine in India

GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled ‘A Randomized, Open-label, Multi-center, Interventional Phase 3 Study of the Efficacy and Safety of Tafenoquine Compared to Primaquine (Both Co-administered With Chloroquine) for the Radical Cure (Relapse Prevention) of Plasmodium Vivax (P. Vivax) Malaria in Indian Participants (Pediatric and Adult Population)’. The study aims to gather efficacy and safety data to support the registration of tafenoquine in India, targeting the treatment of P. Vivax malaria.

GSK’s New Vaccine Study: What Investors Need to Know

GlaxoSmithKline (GSK) is currently conducting a Phase 4 clinical study titled A Phase 4, Single-arm, Open-label, Multi-center Study to Assess the Immune Response and Safety of the Meningococcal Group B Vaccine MenB+OMV NZ When Administered to Healthy Infants From 2 Months of Age in the Republic of Korea. The study aims to evaluate the safety and immune response of the rMenB+OMV NZ vaccine in infants, marking a significant step in ensuring the vaccine’s efficacy and safety for young children.

GSK’s UTI Vaccine Study: A Potential Game-Changer in Preventive Healthcare

GlaxoSmithKline (GSK) is conducting a clinical study titled ‘A Seamless Phase 1/2, Observer-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Immunogenicity of a UTI Vaccine When Administered to Adults 18 Through 64 Years of Age and Clinical Efficacy When Administered to Females 18 Through 64 Years of Age.’ The study aims to evaluate the safety, immune response, and preliminary clinical efficacy of a urinary tract infection (UTI) vaccine in adults aged 18-64, with a focus on females.

GSK’s New Drug Study: A Potential Game Changer for Kidney Disease Treatment

GlaxoSmithKline (GSK) is conducting a study titled A Randomised, Double Blind, Placebo-controlled, Single Ascending Dose, Phase 1a/1b Multi-centre Study in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4771261. The study aims to assess the safety and effects of GSK4771261, a new drug, on both healthy individuals and those with autosomal dominant polycystic kidney disease (ADPKD).

GSK’s RTS, S/AS01E Vaccine Study: A Potential Game Changer in Malaria Prevention

GlaxoSmithKline (GSK) is conducting a study titled ‘A Prospective Study to Evaluate the Safety, Effectiveness and Impact of the RTS, S/AS01E Vaccine in Young Children in Sub-Saharan Africa.’ The study aims to assess the safety and efficacy of the RTS, S/AS01E malaria vaccine, which is intended to protect young children in sub-Saharan Africa as part of routine immunization programs. This study is significant as it evaluates the vaccine’s impact on children’s health in a region heavily affected by malaria.

GSK’s Phase 3b Study on Meningococcal Vaccine: A Potential Game Changer?

GlaxoSmithKline (GSK) is conducting a Phase 3b study titled A Phase 3b, Open-Label, Multi-Center Study to Assess the Immune Response And Safety of The Meningococcal Group B Vaccine Rmenb+Omv Nz When Administered to Healthy Participants Aged 10 To 20 Years Old, Who Were Primed During the First 2 Years Of Life. The study aims to evaluate the immune response and safety of a booster dose of the meningococcal group B vaccine, rMenB+OMV NZ, in adolescents and young adults who were initially vaccinated as infants. This research is significant as it seeks to confirm whether a booster dose enhances immunity in previously vaccinated individuals compared to those who have never received the vaccine.

GSK’s Phase 3 Study on Niraparib and Pembrolizumab: A Potential Game-Changer in NSCLC Treatment

GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)’. The study aims to evaluate the efficacy of niraparib combined with pembrolizumab as a maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC) who have responded to initial chemotherapy. The primary focus is on improving progression-free survival and overall survival rates.

GSK’s Dostarlimab Study: A Potential Game-Changer in Rectal Cancer Treatment

GlaxoSmithKline (GSK) is conducting a Phase 2, single-arm, open-label study titled ‘A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer.’ The study aims to evaluate the effectiveness of dostarlimab monotherapy in patients with untreated stage II/III dMMR/MSI-H locally advanced rectal cancer. The primary objective is to determine if dostarlimab can serve as a standalone treatment, potentially allowing patients to avoid chemotherapy, radiation, and surgery.

GSK Expands Share Buyback Program with Recent Purchase

GlaxoSmithKline (GSK) has announced the purchase of 504,016 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, conducted on August 6, 2025, is part of a non-discretionary agreement with the broker and contributes to the company’s strategy of managing its capital structure. The shares will be held as treasury shares, and following this purchase, GSK holds 239,042,561 ordinary shares in treasury, with a total of 4,076,345,924 ordinary shares in issue. This move is significant for shareholders as it impacts the voting rights and shareholding calculations under the Financial Conduct Authority’s rules.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK’s Promising Study on Belimumab for Systemic Sclerosis Lung Disease

GlaxoSmithKline (GSK) is conducting a significant clinical study titled A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD). The study aims to assess the efficacy and safety of belimumab, a biological treatment, in improving lung function and other symptoms in patients with systemic sclerosis associated interstitial lung disease. This research is crucial as it explores a potential new treatment avenue for a condition with limited options.

GSK and Ideaya’s Promising Study on Tumor-Reducing Drug GSK4418959

GlaxoSmithKline (GSK) and Ideaya Biosciences are conducting a study titled ‘A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)’. The study aims to evaluate the safety, pharmacokinetics, and preliminary effectiveness of GSK4418959, alone or combined with a PD-1 inhibitor, in reducing tumor size in participants with specific genetic tumor characteristics.

GSK’s Phase 3 Study on Multiple Myeloma Treatment: A Potential Game Changer?

GlaxoSmithKline (GSK) is conducting a Phase 3 study titled A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM). The study aims to determine if the BRd combination can extend progression-free survival and improve minimal residual disease negative status compared to the DRd combination in patients with newly diagnosed multiple myeloma who cannot undergo stem cell transplantation.

GSK’s New Pneumococcal Vaccine Study: What Investors Need to Know

GlaxoSmithKline (GSK) is initiating a clinical study titled ‘A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Immunogenicity of An Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age.’ The study aims to assess the safety and immune response of a new vaccine, Pn-MAPS30plus, designed to protect against multiple serotypes of the S. pneumoniae bacteria, potentially offering broader protection than existing vaccines.

GSK Advances Share Buyback Program with Recent Purchase

GSK has announced the repurchase of 498,759 of its own shares as part of its ongoing buyback program, facilitated through Merrill Lynch International. This transaction, executed on August 5, 2025, reflects the company’s strategy to manage its capital structure effectively. The shares will be held as treasury shares, and this move increases the total number of shares held in treasury to 238,538,545, representing 5.85% of the voting rights. This buyback is part of a broader effort to enhance shareholder value and optimize the company’s financial resources.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK’s RSV Vaccine Study: A Potential Game-Changer for Older Adults

GlaxoSmithKline (GSK) is conducting a Phase 3b study titled A Phase 3b, Randomized, Open Label, Multicountry, Multi-center, Extension and Crossover Vaccination Study to Evaluate the Immunogenicity and Safety of Different Revaccination Schedules and Persistence of a Single Dose of the RSVPreF3 OA Vaccine in Adults Aged 60 Years and Above Who Participated in the RSV OA=ADJ-006 Study. The study aims to determine the optimal timing for revaccination, assess long-term immune persistence, and provide the RSVPreF3 OA vaccine to participants who initially received a placebo. This research is significant as it targets respiratory syncytial virus (RSV) prevention in older adults.

GSK’s New Study on GSK5764227: A Potential Game-Changer in Gastrointestinal Cancer Treatment

GlaxoSmithKline (GSK) is conducting a clinical study titled ‘A Phase1b/2, Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors.’ The study aims to assess the safety and effectiveness of GSK5764227, a new biological treatment, in patients with advanced gastrointestinal cancers that cannot be surgically removed. This research is significant as it targets a patient group with limited treatment options.

GSK Continues Share Buyback Program with Recent Purchase

GSK has announced the repurchase of 499,189 of its ordinary shares as part of its ongoing buyback program. The shares were purchased at a volume-weighted average price of 1,391.81 pence and will be held as treasury shares. This transaction is part of a non-discretionary agreement with Merrill Lynch International, aiming to optimize the capital structure and return value to shareholders.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Buyback

GSK has announced the purchase of 496,176 of its own ordinary shares, which will be held as treasury shares, as part of its ongoing buyback program. This move, executed through Merrill Lynch International, reflects GSK’s strategy to manage its capital structure and return value to shareholders, potentially impacting the company’s stock value and market perception.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK’s New Phase 3 Study: A Potential Game-Changer in Lung Cancer Treatment

GlaxoSmithKline (GSK) has announced a new clinical study titled ‘Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC).’ This study aims to evaluate the efficacy and safety of GSK5764227, a novel treatment targeting B7-H3 proteins on cancer cells, in comparison to the standard treatment, topotecan. The study’s significance lies in its potential to improve outcomes for patients with relapsed SCLC by reducing tumor size and extending survival.

GSK’s Bepirovirsen Study: A Potential Game-Changer for Hepatitis B Treatment?

Study Overview: GlaxoSmithKline (GSK) is conducting a Phase 3 multicenter, randomized, double-blind study titled B-Well 1 to assess the efficacy and safety of Bepirovirsen in participants with chronic Hepatitis B who are already receiving nucleos(t)ide analogue treatment. The study aims to confirm the suppression of hepatitis B virus surface antigen (HBsAg) and evaluate the safety and pharmacokinetic profile of Bepirovirsen, highlighting its potential significance in treating chronic Hepatitis B.

GSK’s Mepolizumab Study: A Potential Game-Changer in Severe Asthma Treatment

GlaxoSmithKline (GSK) is conducting a study titled ‘REIMAGINE – Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study’. The study aims to assess the effectiveness of Mepolizumab in achieving clinical remission in patients with severe asthma characterized by an eosinophilic phenotype. This research holds significant potential for improving treatment outcomes for asthma patients.

GSK Announces Total Voting Rights and Capital Structure Update

GSK plc announced its total voting rights and capital structure as of July 31, 2025, in compliance with the Financial Conduct Authority’s rules. The company reported an issued share capital of over 4.3 billion shares, with a total of approximately 4.08 billion voting rights available. This information is crucial for shareholders to determine their interests and obligations under regulatory guidelines.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Advances Share Buyback Program with Recent Purchase

GSK has announced the purchase of 474,100 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds 237,044,421 shares in treasury, representing 5.81% of the voting rights. The buyback program reflects GSK’s commitment to returning value to shareholders and optimizing its financial position.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Buyback

GSK has announced the purchase of 474,100 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, aims to enhance shareholder value and manage the company’s capital structure effectively. Following this purchase, GSK holds 237,044,421 shares in treasury, with a total of 4,078,340,989 shares in issue, impacting the voting rights and shareholding calculations for stakeholders.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £22.90 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK’s Belimumab Study: A Potential Game-Changer for Lupus Treatment?

GlaxoSmithKline (GSK) is conducting a Phase 4 clinical study titled ‘A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus.’ The study aims to evaluate the short-term and long-term efficacy and safety of Belimumab in adults with early systemic lupus erythematosus (SLE) who have ongoing disease activity despite stable initial therapy. This study is significant as it seeks to provide insights into managing SLE, a chronic autoimmune disease.

GSK Enhances Shareholder Value with Latest Share Buyback

GlaxoSmithKline (GSK) plc, a major player in the pharmaceutical industry, has announced the purchase of 288,978 of its own ordinary shares, as part of its ongoing share buyback program. The shares were acquired through Merrill Lynch International, with prices ranging from 1,386.50p to 1,463.50p per share. This move is part of GSK’s strategy to manage its capital structure and return value to shareholders. Following this transaction, GSK holds 236,570,321 shares in treasury, with a total of 4,078,815,089 shares in issue, excluding treasury shares. The percentage of voting rights attributable to the shares held in treasury is now 5.80%.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £22.90 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Enhances Shareholder Value with Strategic Buyback

GSK announced the repurchase of 490,615 of its own shares as part of its ongoing buyback program, executed through its broker Merrill Lynch International. This transaction is part of a larger initiative that has seen the company buy back over 18 million shares since June 2025, reflecting GSK’s strategy to optimize its capital structure and enhance shareholder value.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Reports Strong Q2 2025 Performance and Upward Revision of Financial Guidance

GSK reported strong financial performance in Q2 2025, driven by significant growth in its Specialty Medicines and Vaccines segments, with sales reaching £8.0 billion. The company achieved major milestones in its R&D pipeline, including several new product approvals and ongoing development of promising treatments in oncology and respiratory diseases. GSK has revised its 2025 financial guidance upwards, expecting growth towards the top end of its previous estimates, and continues to focus on shareholder returns through dividends and a share buyback program.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.